Biosimilars – Current Treatment – Endocrinology

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin lispro Sanofi. Subsequently, the EC approved Biocon / Mylan’s insulin glargine biosimilar, Semglee, which the FDA approved in June 2020.

The prescribing behavior of endocrinologists will directly impact the uptake of these products, including insulin brands such as Sanofi’s Lantus and Eli Lilly’s Humalog. Understanding physicians’ attitude and behavior toward biosimilars / follow-on insulins is critical for development and marketing strategies aimed at persuading endocrinologists to prescribe and drive biosimilar / follow-on insulin uptake.

DRG’s primary research with endocrinologists in the United States, France, and Germany allows clients to assess the dynamics determining current and future biosimilar / follow-on insulin uptake within the diabetes space.

This report includes the following topics:

  • Physicians’ current experience prescribing biosimilars / follow-on insulins.
  • The main drivers and barriers influencing biosimilar / follow-on insulin uptake.
  • The impact of cost and clinical data on biosimilar / follow-on insulin uptake.

Scope

Markets covered: United States, France, and Germany.

Primary research: Online quantitative survey of 91 endocrinologists.

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Biosimilars - Current Treatment - Endocrinology
    • Current Treatment Physician Insights Endocrinology US/EU October 2021